Transcriptomics profiling in megalencephaly capillary malformation with impaired PI3K/AKT signaling
Project/Area Number |
15K20911
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Pediatrics
Embryonic/Neonatal medicine
|
Research Institution | Chiba University |
Principal Investigator |
|
Project Period (FY) |
2015-04-01 – 2017-03-31
|
Project Status |
Completed (Fiscal Year 2016)
|
Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2015: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
Keywords | 巨脳症-毛細血管奇形症候群 / PI3K/AKT経路 / PI3KCA関連過成長スペクトラム / microRNA / Hedgehog経路 / Hedghog経路 / 脳形態 / ヘッジホッグ経路 / 巨脳症 |
Outline of Final Research Achievements |
Megalencephaly capillary malformation (MCAP), caused by impaired PI3K/AKT signaling, is a congenital disease with megalencephaly, abnormal connective tissue, and polyductyly. MCAP is involved in PI3KCA related overgrowth spectrum (PROS). We analyzed transcriptosome profiling with fibroblasts, which were derived from healthy and abnormal skin lesion of a PROS patient. In mRNA array, we found 10 genes with over 5-folds upregulation, including WFDC1 and KRT17. In microRNA array, we found down-regulated miR-10a, and up-regulated miR-27b, miR-138, and miR-486. These microRNAs may contribute to pathological overgrowth in PROS via excessive proliferation of fibroblast and osteoblast. Moreover, we established measurement methods to evaluate brain morphology of megalencephaly patients using brain MRI.
|
Report
(3 results)
Research Products
(4 results)
-
[Journal Article] Brain morphology in children with nevoid basal cell carcinoma syndrome.2017
Author(s)
Shiohama, T., Fuji, K., Miyashita, T., Mizuochi, H., Uchikawa, H., Shimojo, N.
-
Journal Title
American Journal of Medical Genetics A
Volume: 173
Issue: 4
Pages: 946-952
DOI
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
-
-